Distribution Deal

Advanced Medical Solutions Grp PLC
12 January 2004

For Immediate Release                                  Monday 12th January 2004

         Advanced Medical Solutions Group plc ('AMS' or 'the Company')

             Announces distribution deal for LiquiBandTM in Germany

Winsford, UK: Advanced Medical Solutions, (AIM: AMS), the global woundcare
technology company, today announces that it has entered into an agreement with
Resorba Clinicare GmbH, a subsidiary of Resorba Wundversorgung GmbH & Co. KG
('Resorba') for distribution of its LiquiBandTM tissue adhesive range in Germany.


LiquiBandTM is a medical adhesive that utilises super-glue technology for closing
wounds for Accident & Emergency (A&E) and surgical applications as an
alternative to stitching or stapling.


AMS's MedLogic division is market leader for medical adhesives in the UK in the
A&E arena and has recently launched LiquiBandTM Surgical, which is a product
designed for closing surgical incisions in the operating theatre. This is the
biggest market opportunity for this technology and it is estimated that 40% of
the current $3 billion suture and staple market could move to medical glues in
the future.


Following the CE Mark approval for sale throughout Europe, MedLogic has been
rolling this product out through its existing distributors and seeking new
partners for key European markets such as Germany, where there is a good
understanding of the surgical wound closure market, a presence in the operating
theatre and a willingness to focus on new, innovative products.


Based in N??renburg, Germany and with branch offices in Austria, Czech Republic
and Russia, Resorba's 24 person sales team currently distributes wound closure
products and surgical specialities for the operating theatre such as sutures,
haemostats (collagen) and hernia meshes.


Commenting on this announcement, Dr Don Evans, Chief Executive of AMS, stated:


'I am delighted that we have found such a suitable partner for our medical
adhesives in Germany. MedLogic's success in achieving market leadership in the
UK A&E market, and our optimism for similar success in the operating theatre, is
based on a highly focussed team being very close to end user customers and being
seen as the experts in medical adhesives.'


'To build successful businesses in other markets requires distribution partners
that are similarly knowledgeable and committed to delivering the enormous
opportunity that this technology offers. I believe that Resorba offers that
expertise and commitment to succeed in Germany.'


Mr. Claus Hiltner, Managing Director of Resorba, added:


'We can see a significant interest in the benefits of using adhesives for
closing surgical wounds, which we are in a strong position to exploit. MedLogic
is an ideal partner for us with its technical back up and success in the UK,
which is the largest and most competitive market in Europe for medical
adhesives.'


'LiquiBandTM Surgical is a very exciting new product that can offer real benefits
to surgeons, nursing staff and patients compared with conventional methods of
wound closure.'


                                    - ENDS -


For further information, please contact:

Advanced Medical Solutions Group plc                    Tel : [phone]
Don Evans, Chief Executive
Mary Tavener, Finance Director
www.admedsol.com
------------------
Buchanan Communications                                Tel: [phone]
Mark Court, Mary-Jane Johnson



Notes to Editors:

Advanced Medical Solutions is a leading company in the development and
manufacture of products for the $15 billion global woundcare market.


Founded in 1991 and currently quoted on AIM, Advanced Medical Solutions is
focused on the design, development and manufacture of innovative and
technologically advanced products for woundcare and other medical applications.


In-house natural and synthetic polymer technology is used to provide advanced
wound dressings based on the moist healing principle. AMS's resources ensure a
unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move from product design and development through to production and delivery
ready for distribution into customer markets.


The acquisition of MedLogic in 2002 has brought AMS products and technology in
cyanoacrylate based tissue adhesives and sealants sold direct to hospitals or
through distributors.


AMS's technology and products currently serve the majority of the key global
markets with strategic partners including 3M, Novartis, Johnson & Johnson,
Molnlycke Healthcare, Coloplast, Smith + Nephew and Beiersdorf.

                      This information is provided by RNS
            The company news service from the London Stock Exchange
         GGGMRLMGDZM